Business ❯ Pharmaceutical Industry ❯ Drug Development

Market Impact

Investor Relations Stock Performance Healthcare Innovations Zantac Sales Regulatory Challenges Consumer Health Eli Lilly Revenue Projections Novo Nordisk Investment Concerns

3 ARTICLES

2w ago

Novartis’ Pelacarsen Fails Phase 3 Outcome Trial

The drug sharply cut the genetic risk marker Lp(a) but did not lower heart attacks, strokes or cardiovascular deaths, raising new questions about the strategy and leaving rivals’ trials as the next test.

4 ARTICLES

3mo ago

Pfizer Lung Cancer Drug Fails to Improve Survival in Late‑Stage Trial

6 ARTICLES

5mo ago

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer